TOP TEN perturbations for P15382 (Homo sapiens)

Organism: Homo sapiens
Gene: P15382
Selected probe(set): 236407_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P15382 (236407_at) across 5392 perturbations tested by GENEVESTIGATOR:

PMA study 2 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):6.201602
Number of Samples:3 / 2
Experimental PMA study 2
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)

Relative Expression (log2-ratio):5.8519893
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (subconfluent)
Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)

Relative Expression (log2-ratio):5.7691627
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (confluent)
Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert.

PMA study 2 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):5.672125
Number of Samples:3 / 2
Experimental PMA study 2 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

PMA study 2 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)

Relative Expression (log2-ratio):4.379195
Number of Samples:3 / 2
Experimental PMA study 2 (shRNA cycT1)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:---
Control cycT1 depletion study 2 (shRNA)
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated.

basal cell carcinoma study 2 / normal skin tissue

Relative Expression (log2-ratio):4.0863276
Number of Samples:2 / 64
Experimental basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).
Control normal skin tissue
Normal skin samples from healthy donors.

nasopharyngeal carcinoma study 1 / nasopharyngeal carcinoma study 3 (adjacent)

Relative Expression (log2-ratio):-4.0051737
Number of Samples:31 / 7
Experimental nasopharyngeal carcinoma study 1
Nasopharyngeal epithelium from Asian patients with nasopharyngeal carcinoma.
Control nasopharyngeal carcinoma study 3 (adjacent)
Histologically normal nasopharyngeal tissue from areas macroscopically not involved in the tumor of patients with primary nasopharyngeal carcinoma.

ovarian tumor study 11 (borderline) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):3.9266834
Number of Samples:8 / 6
Experimental ovarian tumor study 11 (borderline)
Human microdissected tumor cells from the ovary of patients with low-malignant (borderline) tumors of the ovary.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

pediatric meningococcal sepsis study 2 (late) / normal blood sample

Relative Expression (log2-ratio):3.898159
Number of Samples:5 / 3
Experimental pediatric meningococcal sepsis study 2 (late)
Whole blood drawn from children with meningococcal sepsis 24 or 72 hours after admission to the pediatric intensive care unit.
Control normal blood sample
Whole blood drawn from matched control subjects.

Merkel cell carcinoma study 3 (primary) / basal cell carcinoma study 2

Relative Expression (log2-ratio):-3.8403492
Number of Samples:38 / 2
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).